Clinical Trial Record

Return to Clinical Trials

Identify microRNAs in Cachexia in Pancreatic Carcinoma


2022-12-07


2026-05-01


2029-05-01


100

Study Overview

Identify microRNAs in Cachexia in Pancreatic Carcinoma

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.

  • Resectable Pancreatic Adenocarcinoma
  • OTHER: Pancreatic cancer microRNA and messenger RNA expression.
  • OU-SCC-MIRPANCA

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-03-02  

N/A  

2025-02-07  

2022-03-02  

N/A  

2025-02-11  

2022-03-11  

N/A  

2025-02  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Pancreatic Cancer Cohort

All eligible adenocarcinoma pancreatic cancer patients with operable cancer.

OTHER: Pancreatic cancer microRNA and messenger RNA expression.

  • Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Proportion of African American pancreatic cancer patients with weight loss and cachexia.Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.1 - 12 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.Assess fold-change expression differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.1 - 12 months
Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.Assess fold-change expression differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.1 - 12 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Lead Nurse

Phone Number: 405.271.8777

Email: scc-iit-office@ouhsc.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Male or female patient, who is ≥ 18 years old at the time of informed consent. 2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma. 3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy. 4. Ability to provide written informed consent and HIPAA authorization.
    Exclusion Criteria:
    1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection. 2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Ajay Jain, MD, University of Oklahoma Stephenson Cancer Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available